Mithramycin Analogs With Improved Cytotoxicity and Cancer Specificity
Title
Mithramycin Analogs With Improved Cytotoxicity and Cancer Specificity
Description
Division III, honorable mention
Creator
Madeline Jenkin
Marielena Villaran
Contributor
Daniel Scott, Mentor
Abstract
Mithramycin (MTM) is an aureolic acid antibiotic that is produced by many soil bacteria of the genus Streptomyces. A genetically engineered strain of Streptomyces argillaceous, M7W1, produces three MTM analogues: MTM SK, MTM SDK, and MTM SA. MTM SK and MTM SDK have increased cytotoxicity while MTM SA has significantly decreased anticancer activity compared to MTM. MTM SA differs from MTM SK and MTM SDK with the presence of a carboxylic acid on its 3-side chain. This carboxylic acid was used for easy and consistent modification of MTM SA with aromatic side chains to produce new anticancer agents. Cytotoxicity assays were performed to compare the cytotoxicity of these MTM SA analogues to MTM SK/SDK and showed increased anticancer activity. Current work is focused on scaling up these reactions to complete structural characterization with NMR and mass spectrometry.
Collection
Citation
Madeline Jenkin and Marielena Villaran, “Mithramycin Analogs With Improved Cytotoxicity and Cancer Specificity,” RICE (Research, Internships, and Creative Endeavors) Symposium, accessed May 4, 2024, https://ricecentrecollege.omeka.net/items/show/147.